Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis

Next Previous
Trial Profile

A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bamocaftor (Primary) ; Ivacaftor; Tezacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Vertex Pharmaceuticals

Most Recent Events

  • 18 Oct 2018 Results from NCT03224351 and NCT03029455 studies, published in the New England Journal of Medicine.
  • 01 Sep 2017 Status changed from recruiting to completed.
  • 22 Jul 2017 There is a discrepancy in phase of the study. Accordinf to NCT it is phase 1 where as MR and conmpany website states it as phase 2. Presently retained phase as per NCT (phase 1), please update the same on receiving further information.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top